Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California

• Published in: Nature microbiology Vol. 7; no. 2; pp. 277 - 288
• Main Authors: Servellita, Venice, Morris, Mary Kate, Sotomayor-Gonzalez, Alicia, Gliwa, Amelia S, Torres, Erika, Brazer, Noah, Zhou, Alicia, Hernandez, Katherine T, Sankaran, Madeline, Wang, Baolin, Wong, Daniel, Wang, Candace, Zhang, Yueyuan, Reyes, Kevin R, Glasner, Dustin, Deng, Xianding, Streithorst, Jessica, Miller, Steve, Frias, Edwin, Rodgers, Mary, Cloherty, Gavin, Hackett, Jr, John, Hanson, Carl, Wadford, Debra, Philip, Susan, Topper, Scott, Sachdev, Darpun, Chiu, Charles Y
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.02.2022
• Subjects: Adolescent; Adult; Aged; Antibodies; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; BNT162 Vaccine - administration & dosage; BNT162 Vaccine - immunology; Cohort Studies; Coronaviruses; COVID-19; COVID-19 - epidemiology; COVID-19 - immunology; COVID-19 vaccines; COVID-19 Vaccines - immunology; Disease transmission; Female; Genome, Viral; Genomes; Humans; Infections; Male; Middle Aged; Mutation; Phylogeny; San Francisco - epidemiology; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines; Viral Load - statistics & numerical data; Whole Genome Sequencing; Young Adult; San Francisco; San Francisco Bay
• ISSN: 2058-5276; 2058-5276
• DOI: 10.1038/s41564-021-01041-4

Associations between vaccine breakthrough cases and infection by different SARS coronavirus 2 (SARS-CoV-2) variants have remained largely unexplored. Here we analysed SARS-CoV-2 whole-genome sequences and viral loads from 1,373 persons with COVID-19 from the San Francisco Bay Area from 1 February to 30 June 2021, of which 125 (9.1%) were vaccine breakthrough infections. Vaccine breakthrough infections were more commonly associated with circulating antibody-resistant variants carrying ≥1 mutation associated with decreased antibody neutralization (L452R/Q, E484K/Q and/or F490S) than infections in unvaccinated individuals (78% versus 48%, P = 1.96 × 10 ). Differences in viral loads were non-significant between unvaccinated and fully vaccinated cases overall (P = 0.99) and according to lineage (P = 0.09-0.78). Symptomatic vaccine breakthrough infections had comparable viral loads (P = 0.64), whereas asymptomatic breakthrough infections had decreased viral loads (P = 0.023) compared with infections in unvaccinated individuals. In 5 cases with serial samples available for serologic analyses, vaccine breakthrough infections were found to be associated with low or undetectable neutralizing antibody levels attributable to an immunocompromised state or infection by an antibody-resistant lineage. Taken together, our results show that vaccine breakthrough infections are overrepresented by antibody-resistant SARS-CoV-2 variants, and that symptomatic breakthrough infections may be as efficient in spreading COVID-19 as unvaccinated infections, regardless of the infecting lineage.